2.Physicians' Attitudes Toward Guidelines for Stroke: A Survey of Korean Neurologists.
Hyung Min KWON ; Mi Sun OH ; Hye Yeon CHOI ; A Hyun CHO ; Keun Sik HONG ; Kyung Ho YU ; Hee Joon BAE ; Juneyoung LEE ; Byung Chul LEE
Journal of Stroke 2014;16(2):81-85
BACKGROUND AND PURPOSE: Clinical practice guidelines (CPGs) are regarded as an essential guidance tool for practicing physicians. We surveyed physicians in Korea in order to evaluate their attitudes toward the Korean CPGs for stroke. METHODS: We obtained participation agreement for our survey from 27 centers of the 33 most actively contributing to the Korean Stroke Registry. A total of 174 neurologists participated in a questionnaire interview regarding their attitudes toward CPGs for stroke. RESULTS: Of 174 participating neurologists, 65 (37.4%) were stroke neurologists. The average age was 33.6+/-7.1 and 49 (28.2%) were female. Most of the respondents held positive attitudes and opinions regarding the use of the guidelines, whereas only a small percentage (14.9%) responded negatively. More than 60% of the physicians in the survey reported adherence to the Korean CPGs in dyslipidemia management for the secondary prevention of stroke. CONCLUSIONS: The positive attitudes and opinions toward the guidelines imply that physicians' attitudes should not be regarded as a potential barrier to the implementation of Korean CPGs for stroke practiced by general physicians.
Surveys and Questionnaires
;
Dyslipidemias
;
Female
;
Humans
;
Korea
;
Secondary Prevention
;
Stroke*
3.A comparison of Statin treatment algorithms based on the ACC/AHA and Philippine Guidelines for primary prevention of Dyslipidemia in Statin-Naive Filipino patients
Bayani Pocholo Maglinte ; Alex Junia ; Jeremyjones Robles
Journal of the ASEAN Federation of Endocrine Societies 2022;37(2):34-41
Objectives:
This cross-sectional study evaluates the degree of agreement between the 2018 American College of Cardiology/American Heart Association (ACC/AHA2018) and 2020 Philippine Guideline (PG2020) treatment algorithms for the primary prevention of dyslipidemia among Filipinos.
Methodology:
This review included 159 charts of statin-naive Filipinos who are 45-79 years old. Using risk profile and lipid measurements, statin treatment recommendation was determined through the PG2020 algorithm and ACC/AHA-ASCVD Risk Estimator Plus web application. The degree of agreement was measured by Cohen’s kappa statistic with the two algorithms as independent raters.
Results:
A total of 159 patients were included in the final analysis. There was a slight agreement with a kappa coefficient of 0.209 or 4.4% (95% CI 0.078-0.340, p=0.003). Statin treatment was recommended in 69 out of 159 patients (43.4%) by the PG2020 overlapping with ACC/AHA2018 in 56 cases (81.2%). On the other hand, 109 cases (68.6%) were recommended for statin treatment by ACC/AHA2018 overlapping with PG2020 in only 51.4%.
Conclusions
The low degree of agreement between the two treatment algorithms highlights the key demographic and ethnic variations in dyslipidemia management necessitating outcome-based studies to translate these differences. Overestimation of ASCVD risk calculation in the ACC/AHA2018 and consideration of important, unique risk factors among Filipinos favors the applicability of the Philippine guideline.
Dyslipidemias
;
Hypercholesterolemia
;
Algorithms
;
Hydroxymethylglutaryl-CoA Reductase Inhibitors
;
Primary Prevention
4.Differential Benefit of Statin in Secondary Prevention of Acute Myocardial Infarction according to the Level of Triglyceride and High Density Lipoprotein Cholesterol.
Kyung Hwan KIM ; Cheol Hwan KIM ; Myung Ho JEONG ; Youngkeun AHN ; Young Jo KIM ; Myeong Chan CHO ; Wan KIM ; Jong Jin KIM
Korean Circulation Journal 2016;46(3):324-334
BACKGROUND AND OBJECTIVES: The differential benefit of statin according to the state of dyslipidemia has been sparsely investigated. We sought to address the efficacy of statin in secondary prevention of myocardial infarction (MI) according to the level of triglyceride and high density lipoprotein cholesterol (HDL-C) on admission. SUBJECTS AND METHODS: Acute MI patients (24653) were enrolled and the total patients were divided according to level of triglyceride and HDL-C on admission: group A (HDL-C≥40 mg/dL and triglyceride<150 mg/dL; n=11819), group B (HDL-C≥40 mg/dL and triglyceride≥150 mg/dL; n=3329), group C (HDL-C<40 mg/dL and triglyceride<150 mg/dL; n=6062), and group D (HDL-C<40 mg/dL & triglyceride≥150 mg/dL; n=3443). We evaluated the differential efficacy of statin according to the presence or absence of component of dyslipidemia. The primary end points were major adverse cardiac events (MACE) for 2 years. RESULTS: Statin therapy significantly reduced the risk of MACE in group A (hazard ratio=0.676; 95% confidence interval: 0.582-0.785; p<0.001). However, the efficacy of statin was not prominent in groups B, C, or D. In a propensity-matched population, the result was similar. In particular, the benefit of statin in group A was different compared with group D (interaction p=0.042) CONCLUSION: The benefit of statin in patients with MI was different according to the presence or absence of dyslipidemia. In particular, because of the insufficient benefit of statin in patients with MI and dyslipidemia, a different lipid-lowering strategy is necessary in these patients.
Cholesterol, HDL*
;
Dyslipidemias
;
Humans
;
Hydroxymethylglutaryl-CoA Reductase Inhibitors*
;
Myocardial Infarction*
;
Prognosis
;
Secondary Prevention*
;
Triglycerides*
5.Treatment of Dyslipidmia.
Journal of the Korean Medical Association 2010;53(3):204-207
Treatment of dyslipidemia is apparently one of the most important measures for prevention of atherosclerotic cardiovascular diseases. Recent trend reflecting several study results after publication of the ATP-III guideline in 2001 recommends more aggressive target LDL goals in very high risk patients. On the other hand, public health approaches, such as life style modification, to low risk group should not be neglected for primary prevention to avoid life-long medication in undesirably large number of people. Intensity of the treatment must be adjusted after a careful consideration of each patient's global risk, not just by lipid level alone. More attention to dyslipidemia management is needed for both clinical and public health perspectives.
Cardiovascular Diseases
;
Coronary Artery Disease
;
Dyslipidemias
;
Hand
;
Humans
;
Life Style
;
Primary Prevention
;
Public Health
;
Publications
6.Management of Cardiovascular Risk Factors in Elderly Diabetes Mellitus Patients
Journal of Korean Diabetes 2019;20(4):233-238
Tight control of dyslipidemia and hypertension in elderly diabetic patients aged 65 years or older are considered to be very important for the secondary prevention of cardiovascular disease and control of severe diseases associated with macrovascular complications. In addition, in elderly diabetes with risk factors for cardiovascular disease, it is important to control all of the accompanying risk factors together to accomplish the primary prevention of cardiovascular disease. In elderly diabetic patients, thorough control of blood glucose level by itself prevents macrovascular complications. However, it is recommended to perform tight blood glucose control along with other risk factors in consideration of the function and life of the patient. In particular, insulin resistance progresses before the onset of diabetes mellitus and other risk factors for cardiovascular disease. It is important to suppress and prevent the progression of macrovascular complications.
Aged
;
Blood Glucose
;
Cardiovascular Diseases
;
Diabetes Mellitus
;
Dyslipidemias
;
Humans
;
Hypertension
;
Insulin Resistance
;
Primary Prevention
;
Risk Factors
;
Secondary Prevention
7.2011 Update of Scientific Statement for the Primary Prevention of Stroke: Dyslipidemia and Inflammation.
Sang Won HAN ; Hahn Young KIM ; Jong Moo PARK ; Jaseong KOO ; Yong Jin CHO ; Kyusik KANG ; Kyung Ho YU ; Joung Ho RHA ; Ji Hoe HEO ; Sun Uck KWON ; Chang Wan OH ; Hee Joon BAE ; Byung Chul LEE ; Byung Woo YOON ; Chin Sang CHUNG ; Keun Sik HONG
Journal of the Korean Neurological Association 2012;30(3):159-169
BACKGROUND: This scientific statement is intended to provide a systematic review of new evidences in dyslipidemia and inflammation for primary stroke prevention. METHODS: Using a structured literature search, we identified major observational studies, clinical trials, meta-analyses, and updated major guidelines published between July 2007 and November 2010. In addition to the brief summary of earlier evidences employed in the first edition of Korean clinical practice guideline for primary prevention of stroke, we summarized the newly identified evidences. RESULTS: For dyslipidemia, observational studies further support a strong association between ischemic stroke and high total and low-density lipoprotein cholesterol and low high-density lipoprotein cholesterol. Two clinical trials and 6 meta-analyses confirm statin efficacy for primary prevention of stroke in high risk patients. Efficacy of other lipid-lowering agents is not established. For inflammation, inflammatory markers might help to identify patients having high risk for stroke or cardiovascular event and to decide whether statin therapy is indicated, but its usefulness for broad population needs to be confirmed. CONCLUSIONS: Writing committee will continue to keep an eye on upcoming evidences to timely update the guideline for primary stroke prevention in dyslipidemia and inflammation.
Cholesterol
;
Dyslipidemias
;
Eye
;
Humans
;
Hydroxymethylglutaryl-CoA Reductase Inhibitors
;
Inflammation
;
Lipoproteins
;
Meta-Analysis as Topic
;
Practice Guidelines as Topic
;
Primary Prevention
;
Stroke
;
Writing
8.Pharmacological Strategies beyond Statins: Ezetimibe and PCSK9 Inhibitors
Journal of Lipid and Atherosclerosis 2019;8(2):183-191
Dyslipidemia, highly elevated, low-density lipoprotein (LDL) cholesterol, is a major cardiovascular risk factor. Statins have been proven to effectively reduce the risk of atherosclerotic cardiovascular disease (ASCVD) and are recommended as a first-line therapy for the primary and secondary prevention of ASCVD. However, statins may not be sufficient in decreasing LDL cholesterol levels and pose a significant on-treatment residual risk of major cardiovascular events (i.e., residual cholesterol risk) according to meta-analyses of statin trials. Current guidelines for cholesterol management to achieve additional LDL cholesterol reduction and reduce ASCVD risk recommend two hyperlipidemic agents besides statins. Use of ezetimibe, a cholesterol absorption inhibitor, leads to additional LCL cholesterol reduction and decreased ASCVD risk, when added to statin therapy, without raising significant safety concerns. Furthermore, in combination with a mild-to-moderate statin intensity, ezetimibe is used in situations of statin-associated adverse effects such as myalgia and the combination therapy is relatively safer. Monoclonal antibody of proprotein convertase subtilisin/kexin type 9 (PCSK9), alirocumab, and evolocumab, have been approved to lower LDL cholesterol level. While there are drawbacks to the use of PCSK9 inhibitors, including high cost and adverse events such as injection site reaction, they significantly decreased serum LDL cholesterol levels and thereby ASCVD risks when added to maximally tolerated statin therapy.
Absorption
;
Cardiovascular Diseases
;
Cholesterol
;
Cholesterol, LDL
;
Dyslipidemias
;
Ezetimibe
;
Hydroxymethylglutaryl-CoA Reductase Inhibitors
;
Lipoproteins
;
Myalgia
;
Proprotein Convertases
;
Risk Factors
;
Secondary Prevention
9.Risk Factors and Primary and Secondary Prevention of Coronary Heart Disease.
Journal of the Korean Medical Association 2004;47(8):704-713
Atherosclerosis is a major cause of coronary heart disease. Many clinical characteristics and laboratory parameters are known to be related with atherosclerosis and/or coronary heart disease, either epidemiologically or causally. Although the risk to develop cardiovascular disease (CVD) is on a continuum, the risk factor modification was traditionally categorized into primary or secondary prevention based on the presence of clinical CVD. Mega-trials of the primary and secondary prevention have been reported rendering the previous recommendations obsolete. Several guidelines, including the Adult Treatment Panel III, JNC-VII, and the European and British guidelines, were recently released for dyslipidemia and hypertension. Global assessment of CVD risk with multiple risk factors, rather than risk assessment by an individual risk factor is adopted in all of the current guidelines. Absolute risk levels are used for setting of a target level of a given risk factor and for selection of intervention modalities. Complete cessation of smoking, control of dyslipidemia, hypertension, diabetes, and body weight, moderation of alcohol consumption, and guided use of certain medications have been recommended. The hormone replacement therapy was believed to be cardioprotective and recommended for the primary and secondary prevention of coronary heart disease. However, it is no longer recommended for the purpose of the prevention of coronary heart disease. The concept of "the more, the better" is recommended for exercise. Guidelines are ever so changing!
Adult
;
Alcohol Drinking
;
Atherosclerosis
;
Body Weight
;
Cardiovascular Diseases
;
Coronary Disease*
;
Dyslipidemias
;
Hormone Replacement Therapy
;
Humans
;
Hypertension
;
Primary Prevention
;
Risk Assessment
;
Risk Factors*
;
Secondary Prevention*
;
Smoke
;
Smoking
10.The effect of statins on HDL-cholesterol in type 2 diabetic patients.
Jong Ryul PARK ; Jang Hye JUNG ; Jung Youn MOON ; Ji Hye SUK ; Mi Kyung KIM ; Jeong Hyun PARK ; Byung Doo RHEE
Korean Journal of Medicine 2008;74(4):411-417
BACKGROUND/AIMS: Statins have been a mainstay of treatment for primary and secondary prevention of coronary heart disease through their beneficial effect on lipid profile. However, their effect on the HDL cholesterol level has been determined to be equivocal or unclear. This study sought to investigate HDL cholesterol response to statin treatment in type 2 diabetic patients. METHODS: We retrospectively assessed the effect of statins in 217 patients with type 2 diabetes and dyslipidemia through chart review. Patients who were using medications such as fibrates, niacin, or thiazolidinediones, or had a plasma creatinine concentration greater than 1.5 mg/dL, a fasting triglyceride level greater than 300 mg/dL, or chronic liver disease, were excluded from the study. RESULT: The mean level of LDL cholesterol was significantly decreased, and the percentage of patients who achieved the normal LDL cholesterol level was increased in this study. The mean HDL cholesterol level after statin treatment was decreased by 2.3%. The percent change of HDL cholesterol was affected by baseline HDL cholesterol level, percent change of total cholesterol, percent change of LDL cholesterol, and baseline total cholesterol level. When subjects were divided into quintiles according to baseline HDL cholesterol, HDL cholesterol level was found to be increased in the lowest two quintiles while it was decreased in the highest two quintiles. CONCLUSIONS: There were some patients whose HDL cholesterol level was decreased after statin treatment, depending on their baseline HDL cholesterol level. We think further study on the effect of statins on HDL level will be needed in the future.
Cholesterol
;
Cholesterol, HDL
;
Cholesterol, LDL
;
Coronary Disease
;
Creatinine
;
Dyslipidemias
;
Fasting
;
Fibric Acids
;
Humans
;
Liver Diseases
;
Niacin
;
Plasma
;
Retrospective Studies
;
Secondary Prevention
;
Thiazolidinediones